Moderna has reported preliminary clinical ... and there is a measure of sustained response over a six-month period post-booster, albeit a reduction in absolute antibody level compared to one ...

A large U.S. study finds that annual COVID-19 boosters provide significant protection against severe illness but lose ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

December, while Moderna continued to be ... higher than 1.58% recorded last month. XLV, which has a 12.12% weightage in the broader S&P 500 index, rose 4.6% in the last month, compared to S ...

Amid the measles outbreak that the CDC says will 'expand rapidly,' an expert explains how to know if you're protected from ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed ... 19 as we enter the winter months," according to Moderna's chief executive Stéphane ...

Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year on year ... by 28.9% over the next 12 months. While this projection ...

This latest study shows the vaccine does not increase the risk of having a baby born with major birth defects.

The Yale School of Medicine's Dr. Scott Roberts recommends that adults who were vaccinated before 1968 should consider ...

Is Moderna a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting Moderna’s revenue to decline 65.6% year on year to $965.6 million ...

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last three months ... lifted its holdings in shares of Moderna by 365.6% during the 3rd quarter.